Mobile

A phase IIb, controlled, randomized, multicenter, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvante...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-003815-31

A phase IIb, controlled, randomized, multicenter, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with AS03 compared to a second dose of Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly >=60 years previously vaccinated in FLU-LD-002 clinical trial

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess in elderly subjects >=60 years old, the safety and reactogenicity of re-vaccination with the low dose adjuvanted (AS03) influenza vaccine, during the entire study period (30 days). Fluarix will be used as reference.

Critère d'inclusion

  • Re-vaccination against influenza in male and female subjects aged 60 years and older

Liens